Esperion Therapeutics, Inc. (LON:0IIM)

Market Cap	118.97M
Revenue (ttm)	200.91M
Net Income (ttm)	-118.59M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,312
Average Volume	30,311
Open	0.8720
Previous Close	0.9000
Day's Range	0.7401 - 0.8720
52-Week Range	0.7100 - 3.3150
Beta	n/a
RSI	33.35
Earnings Date	May 5, 2025

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2008
• Employees: 304
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IIM

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Financial numbers in USD